CAMP4 Therapeutics Statistics
Share Statistics
CAMP4 Therapeutics has 20.16M
shares outstanding. The number of shares has increased by 1121.26%
in one year.
| Shares Outstanding | 20.16M |
| Shares Change (YoY) | 1121.26% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 63 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 387.05K, so 1.92% of the outstanding
shares have been sold short.
| Short Interest | 387.05K |
| Short % of Shares Out | 1.92% |
| Short % of Float | 2.46% |
| Short Ratio (days to cover) | 9.48 |
Valuation Ratios
The PE ratio is -4.26 and the forward
PE ratio is -0.82.
CAMP4 Therapeutics's PEG ratio is
-0.02.
| PE Ratio | -4.26 |
| Forward PE | -0.82 |
| PS Ratio | 2.13 |
| Forward PS | 0.3 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | -0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for CAMP4 Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | 0 |
| Quick Ratio | 0 |
| Debt / Equity | 0 |
| Debt / EBITDA | -27.57 |
| Debt / FCF | -7.06 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $3,386,000 |
| Profits Per Employee | $-1,695,654.55 |
| Employee Count | 55 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -525K |
| Effective Tax Rate | 0.57% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is -3.12, so CAMP4 Therapeutics's
price volatility has been lower than the market average.
| Beta | -3.12 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 3.4 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 42.02 |
| Average Volume (20 Days) | 240,159 |
Income Statement
In the last 12 months, CAMP4 Therapeutics had revenue of 186.23M
and earned -93.26M
in profits. Earnings per share was -2.52.
| Revenue | 186.23M |
| Gross Profit | 66.98M |
| Operating Income | -8.72M |
| Net Income | -93.26M |
| EBITDA | -8.72M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.52 |
Full Income StatementBalance Sheet
The company has 41.93M in cash and 240.44M in
debt, giving a net cash position of -198.51M.
| Cash & Cash Equivalents | 41.93M |
| Total Debt | 240.44M |
| Net Cash | -198.51M |
| Retained Earnings | -168.82M |
| Total Assets | 281.24M |
| Working Capital | 69.26M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -22.93M
and capital expenditures -11.1M, giving a free cash flow of -34.03M.
| Operating Cash Flow | -22.93M |
| Capital Expenditures | -11.1M |
| Free Cash Flow | -34.03M |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 35.97%, with operating and profit margins of -4.68% and -50.08%.
| Gross Margin | 35.97% |
| Operating Margin | -4.68% |
| Pretax Margin | -49.8% |
| Profit Margin | -50.08% |
| EBITDA Margin | -4.68% |
| EBIT Margin | -4.68% |
| FCF Margin | -18.27% |
